ANIX
NASDAQ
US
Anixa Biosciences, Inc. - Common Stock
$2,55
▼ $-0,17
(-6,25%)
Vol. 69K
4
Punteggio di Qualità
fail
Ricavi ✗
Utile netto ✗
>IPO ✗
Cap. mercato
$102.7M
ROE
-63,1%
Margine
-1090,5%
D/E
0,00
Beta
0,53
52W
$2–$5
Consenso Wall Street
10 analisti · Apr 20262
Acquisto forte
7
Compra
1
Mantieni
0
Vendi
0
Vendita forte
90,0%
Rating Compra
Grafico dei Prezzi
Titoli simili
PYXS
Pyxis Oncology Inc
$71.6M
RCEL
AVITA Medical Inc
$105.2M
MCRB
Seres Therapeutics Inc
P/E 25,0
$134.6M
GOSS
Gossamer Bio Inc
$717.5M
HURA
TuHURA Biosciences Inc
$45.9M
ATYR
aTyr Pharma Inc
$76.7M
FBIO
Fortress Biotech Inc
P/E 28,5
$113.6M
GANX
Gain Therapeutics Inc
$123.8M
INO
Inovio Pharmaceuticals Inc
$119.5M
SERA
Sera Prognostics Inc
$113.9M
Utili
Tasso di battuta: 80,0%| Trimestre | EPS Stimato | EPS Effettivo | Sorpresa |
|---|---|---|---|
| Mar 2026 | $-0,10 | $-0,08 | +$0,02 |
| Dic 2025 | $-0,09 | $-0,09 | $0,00 |
| Set 2025 | $-0,09 | $-0,07 | +$0,02 |
| Giu 2025 | $-0,10 | $-0,09 | +$0,01 |
Ricavi e utili trimestrali
| Trimestre | 2024-0… | 2024-1… | 2025-0… | 2025-0… | 2025-0… | 2025-1… | 2026-0… |
|---|---|---|---|---|---|---|---|
| Ricavi | — | — | — | — | — | — | — |
| Utile netto | — | — | -$3.2M | -$2.8M | -$2.3M | -$2.7M | -$2.6M |
Trend fondamentali
| Metrica | 2025-07-31 | 2025-09-02 | 2025-10-02 | 2025-11-03 | 2025-12-03 | 2026-01-02 |
|---|---|---|---|---|---|---|
| ROE (TTM) | -63.0% | -64.1% | -63.0% | -63.0% | -63.0% | -63.0% |
| P/E (TTM) | — | — | — | — | — | — |
| Net Margin | — | -1090.5% | -1090.5% | -1090.5% | -1090.5% | -1090.5% |
| Gross Margin | — | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% |
| D/E Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Current Ratio | 8.45 | 8.88 | 8.45 | 8.45 | 8.45 | 8.45 |
Rapporti chiave
ROA (TTM)
-59,2%
P/S (TTM)
489,05
P/B
5,6
EPS (TTM)
$-0,34
52W High
$5,46
52W Low
$2,07
$2,07
Intervallo 52 settimane
$5,46
Salute finanziaria
Flusso di cassa libero
-$2.6M
Debito netto
-$1.4M
Liquidità
$1.5M
Debito totale
$193K
Aggiornato al Gen 31, 2026
Як ANIX виглядає на тлі конкурентів у Biotechnology?
Група порівняння: Micro-cap Biotechnology (All) · 528 компаній
Оцінка ANIX vs аналоги Biotechnology
P/E
—
▼
0%
sotto
peer
(18,8)
vs Peer
vs Settore
Sottovalutato
P/S
489,1
▲
3706%
sopra
peer
(12,9)
vs Peer
vs Settore
Sopravvalutato
P/B
5,6
▲
129%
sopra
peer
(2,5)
vs Peer
vs Settore
Sopravvalutato
Дивідендна дохідність
—
▼
0%
sotto
peer
(0,0%)
vs Peer
vs Settore
Rendimento basso
Прибутковість ANIX vs аналоги Biotechnology
ROE
-63,1%
▲
6%
sopra
peer
(-67,3%)
vs Peer
vs Settore
In linea
Net margin
-1090,5%
▼
280%
sotto
peer
(-286,8%)
vs Peer
vs Settore
Debole
Валова маржа
100,0%
▲
27%
sopra
peer
(78,6%)
vs Peer
vs Settore
Debole
ROA
-59,2%
▼
27%
sotto
peer
(-46,7%)
vs Peer
vs Settore
Sotto media
Фінансове здоровʼя ANIX vs аналоги Biotechnology
D/E ratio
0,0
▼
0%
sotto
peer
(0,0)
vs Peer
vs Settore
Debito basso
Поточна ліквідність
8,5
▲
90%
sopra
peer
(4,4)
vs Peer
vs Settore
Liquidità forte
Beta
0,5
▼
46%
sotto
peer
(1,0)
vs Peer
vs Settore
Più volatile
Радар фундаменталів ANIX
ANIX
Mediana peer
Industria
ANIX прибутковість vs борг
Розмір бульбашки = капіталізація · X = чиста маржа · Y = D/E ratio
ANIX vs аналоги: ключові метрики
Attività insider
NeutralAcquisti
0
Vendite
0
BASKIES ARNOLD M
Director · Gen 28
10000 shs
Ultimo 90 giorni
Principali azionisti
Top 5: 10,13%Vanguard Group Inc
4,35%
$3.7M
Laird Norton Wetherby Trust…
1,75%
$1.5M
D.A. Davidson & Co.
1,61%
$1.4M
UBS Group AG
1,37%
$1.2M
Geode Capital Management, L…
1,05%
$895K
Aggiornato al Dic 31, 2025